ADMS / Adamas Pharmaceuticals Inc - Документы SEC, Годовой отчет, Доверенное заявление

AGREEMENT

Exhibit A Exhibit A AGREEMENT The undersigned agree that this Amendment No. 3 to Schedule 13G dated February 14, 2022 relating to the Common Stock, par value $0.001 per share, of Adamas Pharmaceuticals, Inc. shall be filed on behalf of the undersigned. Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd Managing Member /s/ Steven Boyd Steven Boyd

ADMS / Adamas Pharmaceuticals Inc / ARMISTICE CAPITAL, LLC - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

ADMS / Adamas Pharmaceuticals Inc / Stonepine Capital Management, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Adamas Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00548A106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat

ADMS / Adamas Pharmaceuticals Inc / Opaleye Management Inc. Passive Investment

SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Adamas Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00548A106 (CUSIP Number) James Silverman, One Boston Place, 26th Floor, Boston, MA 02108 (Name, Address and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36399 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specifie

As filed with the Securities and Exchange Commission on November 24, 2021

As filed with the Securities and Exchange Commission on November 24, 2021 Registration No.

As filed with the Securities and Exchange Commission on November 24, 2021

As filed with the Securities and Exchange Commission on November 24, 2021 Registration No.

As filed with the Securities and Exchange Commission on November 24, 2021

As filed with the Securities and Exchange Commission on November 24, 2021 Registration No.

As filed with the Securities and Exchange Commission on November 24, 2021

As filed with the Securities and Exchange Commission on November 24, 2021 Registration No.

As filed with the Securities and Exchange Commission on November 24, 2021

S-8 POS 1 tm2133712d5s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on November 24, 2021 Registration No. 333-253396 Registration No. 333-236619 Registration No. 333-230058 Registration No. 333-223147 Registration No. 333-216313 Registration No. 333-210255 Registration No. 333-202467 Registration No. 333-195384 Registration No. 333-249872 UNITED STATES SECURITIES AND EXCHAN

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2021 Adamas Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36399 42-1560076 (State or Other Jurisdiction of Incorporation) (Com

As filed with the Securities and Exchange Commission on November 24, 2021

As filed with the Securities and Exchange Commission on November 24, 2021 Registration No.

As filed with the Securities and Exchange Commission on November 24, 2021

S-8 POS 1 tm2133712d6s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on November 24, 2021 Registration No. 333-253396 Registration No. 333-236619 Registration No. 333-230058 Registration No. 333-223147 Registration No. 333-216313 Registration No. 333-210255 Registration No. 333-202467 Registration No. 333-195384 Registration No. 333-249872 UNITED STATES SECURITIES AND EXCHAN

Amended and Restated Bylaws of Adamas Pharmaceuticals, Inc., dated as of November 24, 2021.

Exhibit 3.2 AMENDED & RESTATED BYLAWS OF ADAMAS PHARMACEUTICALS, INC. (the ?Corporation?) SECTION 1 - STOCKHOLDERS Section 1.1 ???????????Annual Meeting. An annual meeting of the stockholders for the election of directors to succeed those whose term expire and for the transaction of such other business as may properly come before the meeting shall be held at the place, if any, within or without th

Tenth Amended and Restated Certificate of Incorporation of Adamas Pharmaceuticals, Inc., dated as of November 24, 2021.

Exhibit 3.1 TENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ADAMAS PHARMACEUTICALS, INC. FIRST:????????????The name of the corporation is Adamas Pharmaceuticals, Inc. (the ?Corporation?). SECOND:???????The address of its registered office in the State of Delaware is 1209 Orange Street, Corporation Trust Center, Wilmington, New Castle County, Delaware 19801. The name of its registered ag

As filed with the Securities and Exchange Commission on November 24, 2021

S-8 POS 1 tm2133712d3s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on November 24, 2021 Registration No. 333-253396 Registration No. 333-236619 Registration No. 333-230058 Registration No. 333-223147 Registration No. 333-216313 Registration No. 333-210255 Registration No. 333-202467 Registration No. 333-195384 Registration No. 333-249872 UNITED STATES SECURITIES AND EXCHAN

As filed with the Securities and Exchange Commission on November 24, 2021

As filed with the Securities and Exchange Commission on November 24, 2021 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) ADAMAS PHARMACEUTICALS, INC. (Name of Subject Compa

SC TO-T/A 1 tm2133709d2sctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) ADAMAS PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) SUPERNUS REEF, INC. (Offeror) A Wholly Owned Subsidiary of SUPERNUS PHARMACEUTICALS, INC. (Pa

As filed with the Securities and Exchange Commission on November 24, 2021

As filed with the Securities and Exchange Commission on November 24, 2021 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 4) Adamas Pharmaceuticals, Inc. (Name of Subject

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 4) Adamas Pharmaceuticals, Inc. (Name of Subject Company) Adamas Pharmaceuticals, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 00548

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) Adamas Pharmaceuticals, Inc. (Name of Subject

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) Adamas Pharmaceuticals, Inc. (Name of Subject Company) Adamas Pharmaceuticals, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 00548

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) ADAMAS PHARMACEUTICALS, INC. (Name of Subject Compa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) ADAMAS PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) SUPERNUS REEF, INC. (Offeror) A Wholly Owned Subsidiary of SUPERNUS PHARMACEUTICALS, INC. (Parent of Offeror) Common Stock par value $0.0

Press Release issued by Supernus on November 23, 2021.

Exhibit (a)(5)(C) Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer ROCKVILLE, MD, November 23, 2021 ? Supernus Pharmaceuticals, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) Adamas Pharmaceuticals, Inc. (Name of Subject

SC 14D9/A 1 tm2129361d11sc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) Adamas Pharmaceuticals, Inc. (Name of Subject Company) Adamas Pharmaceuticals, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36399 ADAMAS PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Adamas Pharmaceuticals, Inc. (Name of Subject Company) Adamas P

SC14D9C 1 tm2129361d10sc14d9c.htm SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Adamas Pharmaceuticals, Inc. (Name of Subject Company) Adamas Pharmaceuticals, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Cl

Employee Equity Q&A to All Employees of Adamas, first used November 1, 2021.

Exhibit 99.1 From: Adamas Pharmaceuticals <[***]@ccsend.com> Sent: Monday, November 1, 2021 12:55 PM To: Sarah Mathieson <[***]@adamaspharma.com> Subject: Adamas proposed acquisition - employee equity Q&A Hello Team Adamas, We hope the attached Equity Q&A document will assist you with many of the questions you might have about how the equity (stock options, RSUs, ESPP) will work when the proposed

Letter of Transmittal (including Guidelines for Certification of Taxpayer Identification Number on IRS Form W-9).

? ?Exhibit (a)(1)(B)? Letter of Transmittal to Tender Shares of Common Stock of ADAMAS PHARMACEUTICALS, INC.

Email from Sarah Mathieson, Vice President and Head, Corporate Communications of Adamas, dated October 25, 2021, to All Employees of Adamas.

Exhibit (a)(5)(I) From: Adamas Pharmaceuticals <[***]@ccsend.com> Sent: Monday, October 25, 2021 10:10 AM To: Sarah Mathieson <[***]@adamaspharma.com> Subject: An update on the acquisition of Adamas Team Adamas, It has been two weeks since we announced the agreement for Adamas to be acquired by Supernus and we want to continue to communicate updates in a regular and timely manner. We know this new

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) Adamas Pharmaceuticals, Inc. (Name of Subject

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) Adamas Pharmaceuticals, Inc. (Name of Subject Company) Adamas Pharmaceuticals, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 00548

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ADAMAS PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) Super

SC TO-T 1 tm2130834-1sctot.htm SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ADAMAS PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) Supernus Reef, Inc. (Offeror) A Wholly Owned Subsidiary of SUPERNUS PHARMACEUTICALS, INC. (Parent of Offeror) Common

Summary Advertisement as published in The New York Times on October 25, 2021.

Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below).

Form of Contingent Value Rights Agreement.

Exhibit (d)(2) CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [?], 2021 (this ?Agreement?), is entered into by and between Supernus Pharmaceuticals, Inc.

Mutual Non-Disclosure Agreement, dated August 9, 2021, by and among Supernus Pharmaceuticals, Inc. and Adamas Pharmaceuticals, Inc.

CONFIDENTIAL Supernus Pharmaceuticals, Inc. 9715 Key West Avenue Rockville, MD 20850 Attention: Jack Khattar Dear Mr. Khattar: ADAMAS August 9, 2021 In connection with the consideration by Supernus Pharmaceuticals, Inc. (together with its subsidiaries, "you") of a possible negotiated transaction (a "Transaction") involving Adamas Pharmaceuticals, Inc. (together with its subsidiaries, the "Company"

Form of Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.

? ?Exhibit (a)(1)(D) ? Offer to Purchase All Outstanding Shares of Common Stock of ADAMAS PHARMACEUTICALS, INC.

Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.

? ?Exhibit (a)(1)(C) ? Offer to Purchase All Outstanding Shares of Common Stock of ADAMAS PHARMACEUTICALS, INC.

Schedule 14D-9, dated October 25, 2021.

TABLE OF CONTENTS ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Offer to Purchase, dated October 25, 2021.

TABLE OF CONTENTS ?Exhibit (a)(1)(A)? Offer to Purchase All Outstanding Shares of Common Stock of ADAMAS PHARMACEUTICALS, INC.

ADMS / Adamas Pharmaceuticals Inc / HIRSCHMAN ORIN Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment No. 1 Under the Securities Exchange Act of 1934 Adamas Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 00548A106 (CUSIP Number) October 11, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th

ADMS / Adamas Pharmaceuticals Inc / Magnetar Financial LLC - SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* ADAMAS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $.001 (Title of Class of Securities) 00548A106 (CUSIP Number of Class of Securities) Alec N. Litowitz Magnetar Capital LLC 1603 Orrington Ave. Evanston, Illinois 60201 (847) 905-4400 (

Joint Filing Agreement, dated as of October 19, 2021, among the Reporting Persons.

Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k), as promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13D (including amendments thereto) with regard to the common stock of ADAMAS PHARMACEUTICALS, INC., and further agree that this Joint Filing Agreement be includ

Email from Adamas Executive Team to all employees and contractors Adamas, first used on October 13, 2021

Exhibit 99.1 From: [***]@adamaspharma.com To: All employees and contractors to Adamas Subject: What you can (and can?t) communicate around the agreement for Supernus to acquire Adamas Date: Wednesday, October 13, 2021 2:30:33 PM Dear Team Adamas, As Neil mentioned on Monday during our Town Hall, we are at the beginning of a process. The agreement between Adamas and Supernus sets out the terms of t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Adamas Pharmaceuticals, Inc. (Name of Subject Company) Adamas P

SC14D9C 1 tm2129361d7sc14d9c.htm SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Adamas Pharmaceuticals, Inc. (Name of Subject Company) Adamas Pharmaceuticals, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Cla

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Adamas Pharmaceuticals, Inc. (Name of Subject Company) Adamas P

SC14D9C 1 tm2129361d6sc14d9c.htm SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Adamas Pharmaceuticals, Inc. (Name of Subject Company) Adamas Pharmaceuticals, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Cla

Email from James Royster, Senior Director and Analytics, of Adamas, to vendors of Adamas, first used on October 12, 2021 (incorporated by reference to Exhibit 99.1 to the Schedule 14D-9C, filed by Adamas with the SEC on October 13, 2021).

Exhibit 99.1 From: James Royster <[***]@adamaspharma.com> Sent: Tuesday, October 12, 2021 2:13 PM To: Ramon Garcia <[***]@Axtria.Com>; Angeliki Cooney <[***]@Axtria.Com> Cc: Karina Saechao <[***]@adamaspharma.com>; Sarah Mathieson <[***]@adamaspharma.com> Subject: Announcement that Supernus will acquire Adamas Ramon and Angeliki, You may have seen the news that we have signed an agreement for Supe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Adamas Pharmaceuticals, Inc. (Name of Subject Company) Adamas P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Adamas Pharmaceuticals, Inc. (Name of Subject Company) Adamas Pharmaceuticals, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 00548A106 (CUSIP Number

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2021 (October 10, 2021) Adamas Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36399 42-1560076 (State or Other Jurisdiction of I

Agreement and Plan of Merger, dated as of October 10, 2021, by and among Supernus Pharmaceuticals, Inc., Supernus Reef, Inc. and Adamas Pharmaceuticals, Inc., incorporated by reference to Exhibit 2.1 to the Current Report on Form 8- K filed by Adamas with the SEC on October 12, 2021.

Exhibit 2.1 EXECUTION COPY AGREEMENT AND PLAN OF MERGER by and among: ADAMAS PHARMACEUTICALS, INC., SUPERNUS PHARMACEUTICALS, INC., and SUPERNUS REEF, INC. Dated as of October 10, 2021 TABLE OF CONTENTS Page Article 1 DEFINITIONS 2 Section 1.1 Definitions 2 Article 2 THE OFFER 14 Section 2.1 The Offer. 14 Section 2.2 Company Actions. 16 Article 3 MERGER TRANSACTION 17 Section 3.1 Merger of Purchas

Sales Force Memo re: Acquisition by Supernus, first used on October 11, 2021

Exhibit 99.3 SALES FORCE MEMO Subject: Acquisition by Supernus Dear Sales Team, As you?ve heard, today we announced that Adamas will be acquired by Supernus. Team Adamas has collectively built a business we can be proud of ? one that the Supernus management team believes they can invest in and continue to grow. Your hard work and dedication has been a huge part of making this happen. Thank you for

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Adamas Pharmaceuticals, Inc. (Name of Subject Company) Adamas P

SC 14D9 1 tm2129361d3sc14d9.htm SC 14D9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Adamas Pharmaceuticals, Inc. (Name of Subject Company) Adamas Pharmaceuticals, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Clas

Joint Press Release issued by Supernus and Adamas on October 11, 2021 (incorporated by reference to Exhibit 99.1 to the Schedule TO-C filed by Supernus on October 12, 2021).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2021 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or o

Email from Sarah Mathieson, Vice President and Head, Corporate Communications of Adamas, to key partners of Adamas, first used on October 12, 2021

Exhibit 99.1 From: Sarah Mathieson Sent: Tuesday, October 12, 2021 12:53 PM To: Jorie Parwani <[***]>; Richard Waidelich <[***]>; Leigh Cocanougher <[***]>; Jenna Deidel <[***]> Cc: Jennifer Chang <[***]>; Katie Feeley <[***]> Subject: The announcement that Supernus will acquire Adamas Dear DPF team You may have seen the news yesterday that we have entered into an agreement for Supernus to acquire

Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio

Exhibit 99.1 Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio October 11, 2021 n Acquisition of two marketed products diversifies and accelerates revenue and cash flow n Expected to be significantly accretive in 2022 n Potential synergies of $60 million to $80 million in year one due to strong overlap with existing infrastructure n Total considerat

Manager Talking Points re: Acquisition by Supernus, first used on October 11, 2021

Exhibit 99.2 MANAGER TALKING POINTS ? Team Adamas has collectively built a business we can be proud of ? one that the Supernus management team believes they can invest in and continue to grow as part of their organization. ? There will now be a process of regulatory and other approvals before the deal is closed and our transaction/handover period begins. If the approval process goes quickly, we an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Adamas Pharmaceuticals, Inc. (Name of Subject Company) Adamas P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Adamas Pharmaceuticals, Inc. (Name of Subject Company) Adamas Pharmaceuticals, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 00548A106 (CUSIP Number

Email from Neil McFarlane, the Chief Executive Officer of Adamas, to employees, first used on October 11, 2021

Exhibit 99.1 From: Marie Velasco [*****] On Behalf Of Neil F. McFarlane Sent: Monday, October 11, 2021 3:42 AM To: Adamas Employees All [*****] Subject: Today's announcement that Supernus will acquire Adamas Dear Team Adamas, Today, we announced that Adamas has entered into an agreement for Supernus to acquire our company. Supernus shares our strategic vision to unlock the potential of our neurolo

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction of incorporation) (Commis

Amendment No. 1 ASSET PURCHASE AGREEMENT

Exhibit 2.2 Certain information identified by ?[*]? has been excluded from the exhibit because it is both not material and is the type of information that the registrant treats as private or confidential. Amendment No. 1 to ASSET PURCHASE AGREEMENT This Amendment No. 1 to Asset Purchase Agreement (?Amendment?) is entered into on April 27, 2021 (the ?Amendment Effective Date?) by and between Adamas

Adamas reports second quarter 2021 financial results Second quarter 2021 total revenues of $22.0 million, a 17% increase over second quarter 2020 GOCOVRI new paid prescriptions of 730, a 97% increase over second quarter 2020

Exhibit 99.1 Adamas reports second quarter 2021 financial results Second quarter 2021 total revenues of $22.0 million, a 17% increase over second quarter 2020 GOCOVRI new paid prescriptions of 730, a 97% increase over second quarter 2020 EMERYVILLE, Calif., August 9, 2021 - Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningfu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36399 ADAMAS PHARMACEUTICAL

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2021 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction of incorporation) (Commissi

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2021 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction of incorporation) (Commissi

Adamas reports first quarter 2021 financial results First quarter 2021 total revenues of $19.3 million, a 33% increase over first quarter 2020 GOCOVRI New paid prescriptions of 590, an 18% increase over first quarter 2020

Exhibit 99.1 Adamas reports first quarter 2021 financial results First quarter 2021 total revenues of $19.3 million, a 33% increase over first quarter 2020 GOCOVRI New paid prescriptions of 590, an 18% increase over first quarter 2020 EMERYVILLE, Calif., May 10, 2021 - Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful dif

ADAMAS PHARMACEUTICALS, INC. RESTRICTED STOCK UNIT GRANT NOTICE PERFORMANCE RESTRICTED STOCK UNIT (2014 EQUITY INCENTIVE PLAN)

ADAMAS PHARMACEUTICALS, INC. RESTRICTED STOCK UNIT GRANT NOTICE PERFORMANCE RESTRICTED STOCK UNIT (2014 EQUITY INCENTIVE PLAN) Adamas Pharmaceuticals, Inc. (the “Company”), pursuant to Section 6(b) of the Company’s 2014 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Performance Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36399 ADAMAS PHARMACEUTICA

Adamas-Zydus Binding Term Sheet

Exhibit 10.1 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type of information that Adamas Pharmaceuticals, Inc. treats as private or confidential. Execution Version Adamas-Zydus Binding Term Sheet Parties Adamas Pharma, LLC (“Adamas”) and Zydus Worldwide DMCC and Zydus Pharmaceuticals (US

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction of incorporation) (Commissi

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

Adamas Definitive Proxy Statement (incorporated by reference to Schedule 14A, filed by Adamas with the SEC on April 19, 2021).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ___)* Adamas Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Adamas Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00548A106 (CUSIP Number) February 25, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate

12,500,000 Shares Common stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-234570 PROSPECTUS SUPPLEMENT (To prospectus dated December 2, 2019) 12,500,000 Shares Common stock We are offering 12,500,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol “ADMS.” On February 24, 2021, the last reported sale price of our common stock was $4.73 per share. Investing in our com

ADAMAS PHARMACEUTICALS, INC. (a Delaware corporation) 12,500,000 Shares of Common Stock UNDERWRITING AGREEMENT

EX-1.1 2 adms8-k022021ex11.htm EX-1.1 Exhibit 1.1 EXECUTION VERSION ADAMAS PHARMACEUTICALS, INC. (a Delaware corporation) 12,500,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: February 24, 2021 #94192013v6 ADAMAS PHARMACEUTICALS, INC. (a Delaware corporation) 12,500,000 Shares of Common Stock UNDERWRITING AGREEMENT February 24, 2021 SVB Leerink LLC William Blair & Company, L.L.C. as Repr

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2021 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction of incorporation) (Com

SUBJECT TO COMPLETION, DATED FEBRUARY 24, 2021

Filed Pursuant to Rule 424(b)(5) Registration No. 333-234570 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement is not an offer to sell nor does it seek an offer to buy these securities i

Adamas Pharmaceuticals, Inc. 2016 Inducement Plan (incorporated by reference to Exhibit 10.6 to Annual Report on Form 10-K, filed by Adamas with the SEC on February 23, 2021).

Exhibit 10.6 ADAMAS PHARMACEUTICALS, INC. 2016 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 4, 2016; AS AMENDED: FEBRUARY 20, 2021 TERMINATION DATE: MARCH 3, 2026 1. GENERAL. (a) Purpose. Awards under the Plan are intended to provide (1) an inducement material for certain individuals to enter into employment with the Company within the meaning of Rule 5635(c)(4) of the NASDAQ Listing R

Adamas Reports Fourth Quarter and Full Year 2020 Financial Results Fourth Quarter 2020 total revenues of $21.0 million, a 29% increase over fourth quarter 2019 Full Year 2020 total revenues of $74.5 million, a 36% increase over 2019 Second indication

EX-99.1 2 adms2020q4991.htm EX-99.1 Exhibit 99.1 Adamas Reports Fourth Quarter and Full Year 2020 Financial Results Fourth Quarter 2020 total revenues of $21.0 million, a 29% increase over fourth quarter 2019 Full Year 2020 total revenues of $74.5 million, a 36% increase over 2019 Second indication received February 2021 for GOCOVRI as an adjunctive treatment to levodopa/carbidopa in Parkinson’s d

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36399 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as s

Adamas Pharmaceuticals, Inc. Amended and Restated Executive Severance Plan

Exhibit 10.19 Adamas Pharmaceuticals, Inc. Amended and Restated Executive Severance Plan 1.Purpose and Eligibility. This Amended and Restated Executive Severance Plan (the “Plan”) is intended to provide severance benefits to employees of Adamas Pharmaceuticals, Inc. (the “Company”) who hold the title of Vice President or above (each, a “Participant”). The Plan, as amended and restated, is effectiv

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2021 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction of incorporation) (Com

ADAMAS PHARMACEUTICALS, INC. SUBSIDIARIES NAME OF SUBSIDIARY JURISDICTION OF INCORPORATION Adamas Pharma, LLC Delaware, USA

Exhibit 21.1 ADAMAS PHARMACEUTICALS, INC. SUBSIDIARIES NAME OF SUBSIDIARY JURISDICTION OF INCORPORATION Adamas Pharma, LLC Delaware, USA

COMPENSATION ARRANGEMENTS WITH EXECUTIVE OFFICERS

Exhibit 10.22 COMPENSATION ARRANGEMENTS WITH EXECUTIVE OFFICERS Annual Cash Compensation The Compensation Committee of the board of directors sets the annual base salary for each of Adamas Pharmaceuticals, Inc.?s executive officers. The annual base salary and target bonus award percentage for the executive officers, to be effective March 1, 2021, are as follows: Executive Officer Annual Base Salar

- S-8

As filed with the Securities and Exchange Commission on February 23, 2021 Registration No.

AMENDMENT NO. 3 TO LOAN AGREEMENT

EX-10.31 6 adms10k2020ex1031.htm EX-10.31 Exhibit 10.31 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely be competitively harmful if publicly disclosed. Execution Version AMENDMENT NO. 3 TO LOAN AGREEMENT This AMENDMENT NO. 3 TO LOAN AGREEMENT (this “Amendment”), dated as of December 1,

ASSET PURCHASE AGREEMENT Osmotica Pharmaceutical US LLC, a Delaware limited liability company, Osmotica, Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság, a corporation organized under the laws of Hungary, Osmotica Holdings US LLC, a Delawa

Exhibit 2.1 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely be competitively harmful if publicly disclosed. Execution Version ASSET PURCHASE AGREEMENT between: Osmotica Pharmaceutical US LLC, a Delaware limited liability company, Osmotica, Kereskedelmi és Szolgáltató Korlátolt Felelõss

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Adamas Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 00548A106 (CUSIP Number) February 16, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Adamas Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Adamas Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00548A106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Adamas Pharmaceuticals Inc. (Name of Issuer) Common Shares (Title of Class of Securities) (CUSIP Number)

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Adamas Pharmaceuticals Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 00548A106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) ADAMAS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) ADAMAS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00548A106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa

Entry into a Material Definitive Agreement - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2021 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction of incorporation) (Comm

Adamas Provides Preliminary Fourth Quarter and Full Year 2020 Total Revenues and Key Business Drivers for 2021 -- Total revenues expected to be $20.8 million for fourth quarter 2020 and $74.2 million for full year 2020 -- -- Product sales of GOCOVRI®

Exhibit 99.1 Adamas Provides Preliminary Fourth Quarter and Full Year 2020 Total Revenues and Key Business Drivers for 2021 - Total revenues expected to be $20.8 million for fourth quarter 2020 and $74.2 million for full year 2020 - - Product sales of GOCOVRI® expected to be $19.8 million for fourth quarter 2020 and $71.2 million for full year 2020 - - Total prescriptions of GOCOVRI of approximate

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2021 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction of incorporation) (Comm

Entry into a Material Definitive Agreement - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2020 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction of incorporation) (Comm

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2020 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction of incorporation) (Com

- S-8

As filed with the Securities and Exchange Commission on November 5, 2020 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction of incorporation) (Comm

Adamas Reports Third Quarter 2020 Financial Results Third quarter 2020 total revenues of $20.2 million, a 45% increase over third quarter 2019 Third quarter 2020 GOCOVRI® product sales of $19.0 million, a 36% increase over third quarter 2019 Total pa

Exhibit 99.1 Adamas Reports Third Quarter 2020 Financial Results Third quarter 2020 total revenues of $20.2 million, a 45% increase over third quarter 2019 Third quarter 2020 GOCOVRI® product sales of $19.0 million, a 36% increase over third quarter 2019 Total paid prescriptions of 7,930, a 19% increase over third quarter 2019 EMERYVILLE, Calif., November 5, 2020 - Adamas Pharmaceuticals, Inc. (Na

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36399 ADAMAS PHARMACEU

ADAMAS PHARMACEUTICALS, INC. 2016 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 4, 2016; AS AMENDED: OCTOBER 2, 2020 TERMINATION DATE: MARCH 3, 2026

Exhibit 10.2 ADAMAS PHARMACEUTICALS, INC. 2016 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 4, 2016; AS AMENDED: OCTOBER 2, 2020 TERMINATION DATE: MARCH 3, 2026 1. GENERAL. (a) Purpose. Awards under the Plan are intended to provide (1) an inducement material for certain individuals to enter into employment with the Company within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rul

July 15, 2020

Exhibit 10.1 July 15, 2020 Via Hand Delivery Rajiv Patni c/o Adamas Pharmaceuticals, Inc. Re: Separation and Consulting Agreement Extension Dear Rajiv: Thank you so much for agreeing to extend the term of the Consulting Period under your Separation and Consulting Agreement dated as of February 20, 2020 (the “Agreement”). The provisions of each of the first paragraph of Section 2 and of Section 2(j

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2020 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction of incorporation) (Commi

ADMS / Adamas Pharmaceuticals, Inc. / Opaleye Management Inc. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ADAMAS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00548A106 (CUSIP Number) August 11, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t

Adamas Reports Second Quarter 2020 Financial Results Second quarter 2020 GOCOVRI® product sales of $18.0 million, a 41% increase over second quarter 2019 Total paid prescriptions grew to 8,150, a 32% increase over second quarter 2019

Exhibit 99.1 Adamas Reports Second Quarter 2020 Financial Results Second quarter 2020 GOCOVRI® product sales of $18.0 million, a 41% increase over second quarter 2019 Total paid prescriptions grew to 8,150, a 32% increase over second quarter 2019 EMERYVILLE, Calif., August 6, 2020 - Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36399 ADAMAS PHARMACEUTICAL

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 6, 2020 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction of incorporation) (Commiss

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2020 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36399 (Commission File Nu

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2020 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36399 (Commission File Num

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2020 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36399 (Commission File Num

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36399 ADAMAS PHARMACEUTICA

NON-EMPLOYEE DIRECTOR COMPENSATION

Exhibit 10.3 NON-EMPLOYEE DIRECTOR COMPENSATION Annual Cash Compensation The annual cash compensation payable to non-employee directors of Adamas Pharmaceuticals, Inc., or Adamas, to take effect immediately following the Adamas 2020 annual meeting, is as follows, payable quarterly in arrears: Retainer Amount Board Member Compensation Board Member $45,000 Chair of the Board (additional retainer) $6

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 7, 2020 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36399 (Commission File Numbe

Adamas Reports First Quarter 2020 Financial Results First quarter 2020 GOCOVRI® product sales of $14.5 million, a 24% increase over first quarter 2019 Total paid prescriptions grew approximately 24% to 7,210 over first quarter 2019

Exhibit 99.1 Adamas Reports First Quarter 2020 Financial Results First quarter 2020 GOCOVRI® product sales of $14.5 million, a 24% increase over first quarter 2019 Total paid prescriptions grew approximately 24% to 7,210 over first quarter 2019 EMERYVILLE, Calif., May 7, 2020 - Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meani

[Remainder of Page Intentionally Left Blank]

Exhibit 10.2 February 20, 2020 Via Hand Delivery Rajiv Patni c/o Adamas Pharmaceuticals, Inc. Re: Separation and Consulting Agreement Dear Rajiv: This letter sets forth the substance of the separation and consulting agreement (the “Agreement”) that Adamas Pharmaceuticals, Inc. (the “Company”) is offering to you to aid in your employment transition. 1.SEPARATION DATE. You have informed the Company

[Remainder of Page Intentionally Left Blank]

Exhibit 10.1 January 9, 2020 Via Hand Delivery Jennifer Rhodes c/o Adamas Pharmaceuticals, Inc. Re: Separation and Consulting Agreement Dear Jennifer: This letter sets forth the substance of the separation and consulting agreement (the “Agreement”) that Adamas Pharmaceuticals, Inc. (the “Company”) is offering to you to aid in your employment transition. 1.SEPARATION DATE. You have informed the Com

Schedule 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

ADAMAS PHARMACEUTICALS, INC. 2016 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 4, 2016; AS AMENDED: FEBRUARY 24, 2020 TERMINATION DATE: MARCH 3, 2026

Exhibit 10.6 ADAMAS PHARMACEUTICALS, INC. 2016 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 4, 2016; AS AMENDED: FEBRUARY 24, 2020 TERMINATION DATE: MARCH 3, 2026 1. GENERAL. (a) Purpose. Awards under the Plan are intended to provide (1) an inducement material for certain individuals to enter into employment with the Company within the meaning of Rule 5635(c)(4) of the NASDAQ Listing R

Adamas-Sandoz Binding Term Sheet

Exhibit 10.41 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely be competitively harmful if publicly disclosed. Execution Version Adamas-Sandoz Binding Term Sheet Parties • Adamas Pharma, LLC (“Adamas”) and Sandoz, Inc. (“Sandoz”) Overview Adamas and Sandoz have had discussions to resolv

As filed with the Securities and Exchange Commission on February 25, 2020

As filed with the Securities and Exchange Commission on February 25, 2020 Registration No.

AMENDMENT NO. 2 TO LOAN AGREEMENT

Exhibit 10.37 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely be competitively harmful if publicly disclosed. Executed Version AMENDMENT NO. 2 TO LOAN AGREEMENT This Amendment No. 2 to Loan Agreement (the “Amendment”) is made of this 2 day of January, 2020 by and between the entities m

Adamas Reports Fourth Quarter and Full Year 2019 Financial Results - Full year 2019 GOCOVRI® product sales of $54.6 million, a 60% increase over 2018; total paid prescriptions grew approximately 66% to 25,780 - Fourth quarter 2019 GOCOVRI® product sa

Exhibit 99.1 Adamas Reports Fourth Quarter and Full Year 2019 Financial Results - Full year 2019 GOCOVRI® product sales of $54.6 million, a 60% increase over 2018; total paid prescriptions grew approximately 66% to 25,780 - Fourth quarter 2019 GOCOVRI® product sales of $16.3 million, a 23% increase over fourth quarter 2018; total paid prescriptions grew approximately 25% to 7,160 over fourth quart

ADAMAS PHARMACEUTICALS, INC. SUBSIDIARIES NAME OF SUBSIDIARY JURISDICTION OF INCORPORATION Adamas Pharma, LLC Delaware, USA

EX-21.1 6 adms10k2019ex211.htm EX-21.1 Exhibit 21.1 ADAMAS PHARMACEUTICALS, INC. SUBSIDIARIES NAME OF SUBSIDIARY JURISDICTION OF INCORPORATION Adamas Pharma, LLC Delaware, USA

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2020 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36399 (Commission Fil

Exhibit 4.4

Exhibit 4.4 DESCRIPTION OF ADAMAS PHARMACEUTICALS, INC. COMMON STOCK Our authorized capital stock consists of 100,000,000 shares of common stock, $0.001 par value per share, and 5,000,000 shares of preferred stock, $0.001 par value per share. A description of material terms and provisions of our certificate of incorporation and bylaws affecting the rights of holders of our common stock is set fort

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36399 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as s

ADMS / Adamas Pharmaceuticals, Inc. / Went Gregory T - SC 13G/A Passive Investment

CUSIP No. 00548A 106 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Adamas Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 00548A 106 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

ADMS / Adamas Pharmaceuticals, Inc. / Point72 Asset Management, L.P. - SCHEDULE 13G/A, AMENDMENT #3 Passive Investment

240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.3)* (Name of Issuer) Adamas Pharmaceuticals, Inc. (Title of Class of Securities) Common Stock, Par Value $0

ADMS / Adamas Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

ADMS / Adamas Pharmaceuticals, Inc. / Broadfin Capital, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

ADMS / Adamas Pharmaceuticals, Inc. / Stonepine Capital Management, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Adamas Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00548A106 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat

ADMS / Adamas Pharmaceuticals, Inc. / MACQUARIE GROUP LTD - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Adamas Pharmaceuticals Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 00548A106 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

ADMS / Adamas Pharmaceuticals, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment

SC 13G/A 1 ADMSSC13GA1Feb20.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ADAMAS PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 00548A106 (CUSIP Number) DECEMBER 31, 2019 (Date of event which requires filing of this statement) Check

ADMS / Adamas Pharmaceuticals, Inc. / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Adamas Pharmaceuticals Inc (Name of Issuer) Common Stock (Title of Class of Securities) 00548A106 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate

Adamas Provides Preliminary Fourth Quarter and Full Year 2019 GOCOVRI® Product Sales and Outlines Key Priorities for 2020 -- Product sales expected to be approximately $16.3 million for fourth quarter 2019 and approximately $54.6 million for full yea

Exhibit 99.1 Adamas Provides Preliminary Fourth Quarter and Full Year 2019 GOCOVRI® Product Sales and Outlines Key Priorities for 2020 - Product sales expected to be approximately $16.3 million for fourth quarter 2019 and approximately $54.6 million for full year 2019 - - Total prescriptions of approximately 7,160 for fourth quarter 2019 and approximately 25,780 for full year 2019 - EMERYVILLE, Ca

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 2, 2020 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36399 (Commission File N

Entry into a Material Definitive Agreement

8-K 1 adms8-kitem101.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 30, 2019 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporatio

Common Stock

424B5 1 admsform424b5atm12219.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No.: 333-234570 Prospectus $50,000,000 Common Stock We have entered into a sales agreement, or the sales agreement, with Cowen and Company, LLC, or Cowen, relating to shares of our common stock offered by this prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our com

Common Stock Preferred Stock Debt Securities

Filed Pursuant to Rule 424(b)(5) Registration No.: 333-234570 Prospectus $200,000,000 Common Stock Preferred Stock Debt Securities Warrants From time to time, we may offer and sell up to an aggregate amount of $200,000,000 of any combination of the securities described in this prospectus, either individually or in combination. We may also offer common stock or preferred stock upon conversion of de

ADMS / Adamas Pharmaceuticals, Inc. CORRESP - -

ADAMAS PHARMACEUTICALS, INC. 1900 Powell Street, Suite 1000 Emeryville, CA 94608 (510) 450-3500 November 25, 2019 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ada D. Sarmento Joe McCann RE: Adamas Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-234570 Ladies and Gentlemen: Adamas Pha

ADMS / Adamas Pharmaceuticals, Inc. CORRESP - -

BRETT D. WHITE +1 650 843 5191 [email protected] VIA EDGAR AND FEDEX November 20, 2019 United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ada Sarmento Joe McCann Re: Adamas Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed November 7, 2019 File No. 333-234570 Dear Ms. Sarmento and Mr. McCann: On behalf of our

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 4, 2019 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36399 (Commission File

Adamas Reports Third Quarter 2019 Financial Results - Third quarter GOCOVRI® product sales of $13.9 million; total prescriptions grew to approximately 6,640 - Topline results from INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in

Exhibit 99.1 Adamas Reports Third Quarter 2019 Financial Results - Third quarter GOCOVRI® product sales of $13.9 million; total prescriptions grew to approximately 6,640 - Topline results from INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in patients with multiple sclerosis (MS) expected second half December 2019 EMERYVILLE, Calif., November 7, 2019 - Adamas Pharmaceuticals, I

ADMS / Adamas Pharmaceuticals, Inc. S-3 - - S-3

As filed with the Securities and Exchange Commission on November 7, 2019 Registration No.

ADAMAS PHARMACEUTICALS, INC. $50,000,000 COMMON STOCK SALES AGREEMENT

Exhibit 1.2 ADAMAS PHARMACEUTICALS, INC. $50,000,000 COMMON STOCK SALES AGREEMENT November 7, 2019 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Adamas Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees th

CONFIDENTIAL 1900 Powell St. Suite 1000 Emeryville, CA 94608 Tel|510.450.3500 Fax|510.428.0519

Exhibit 10.3 DATE: September 12, 2019 Neil McFarlane Dear Neil: We are very excited to have you join Adamas Pharmaceuticals, Inc. (the “Company”). In this letter, I would like to set forth the terms and conditions of your employment relationship with the Company. Title and Responsibilities. I am pleased to offer you the full-time position of Chief Executive Officer working at our offices in Emeryv

ADAMAS PHARMACEUTICALS, INC, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20__ Debt Securities

Exhibit 4.4 ADAMAS PHARMACEUTICALS, INC, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8

By: /s/ David L. Mahoney David Mahoney On Behalf of the Board of Directors

Exhibit 10.2 EXECUTION COPY September 11, 2019 Via Hand Delivery Greg Went c/o Adamas Pharmaceuticals, Inc. Re: Transition, Separation, and Consulting Agreement Dear Greg: This letter sets forth the substance of the transition, separation, and consulting agreement (the “Agreement”) that Adamas Pharmaceuticals, Inc. (the “Company”) is offering to you to aid in your employment transition. 1.SEPARATI

ADAMAS PHARMACEUTICALS, INC. AND _____________, AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF __________ ADAMAS PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT

Exhibit 4.8 ADAMAS PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF ADAMAS PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between ADAMAS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”) and [●], a [corporation] [national banking association] or

ADAMAS PHARMACEUTICALS, INC. AND _____________, AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF __________ ADAMAS PHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT

Exhibit 4.6 ADAMAS PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF ADAMAS PHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between, ADAMAS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”) and [●], a [corporation] [national banking association] organized

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36399 ADAMAS PHARMACEU

ADAMAS PHARMACEUTICALS, INC. AND _____________, AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF __________ ADAMAS PHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT

Exhibit 4.7 ADAMAS PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF ADAMAS PHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between ADAMAS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”) and [●], a [corporation] [national banking association] or

/s/ Alfred Merriweather Alfred Merriweather August 23, 2019 Date

EX-10.1 2 adms10qq32019ex101.htm EX-10.1 Exhibit 10.1 August 7, 2019 Alfred Merriweather c/o Adamas Pharmaceuticals, Inc. Re: Separation and Consulting Agreement Dear Alf: This letter sets forth the substance of the separation and consulting agreement (the “Agreement”) that Adamas Pharmaceuticals, Inc. (the “Company”) is offering to you to aid in your employment transition. 1.SEPARATION DATE. We h

ADMS / Adamas Pharmaceuticals, Inc. CORRESP - -

CORRESP 1 filename1.htm October 7, 2019 VIA EDGAR AND FEDEX United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Rolf Sundwall Sasha Parikh Re: Adamas Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2018 Filed March 4, 2019 File No. 001-36399 Ladies and Gentlemen: Adamas Pharmaceuticals, Inc. (the “Com

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 11, 2019 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36399 (Commission Fil

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 4, 2019 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36399 (Commission File Nu

Adamas Reports Second Quarter 2019 Financial Results - Second quarter GOCOVRI® product sales of $12.7 million; total prescriptions grew to approximately 6,160 - INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in patients with multi

Exhibit 99.1 Adamas Reports Second Quarter 2019 Financial Results - Second quarter GOCOVRI® product sales of $12.7 million; total prescriptions grew to approximately 6,160 - INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in patients with multiple sclerosis (MS) enrollment completed, with topline results expected late Q4 2019 - Alfred Merriweather, CFO, to retire; Chris Prentiss

AMENDMENT NO. 1 TO AMENDED AND RESTATED COMMERCIAL SUPPLY AGREEMENT (Amantadine HCl extended release capsules)

Exhibit 10.3 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely be competitively harmful if publicly disclosed. AMENDMENT NO. 1 TO AMENDED AND RESTATED COMMERCIAL SUPPLY AGREEMENT (Amantadine HCl extended release capsules) This Amendment No. 1 (this “Amendment”) is effective as of June 27

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36399 ADAMAS PHARMACEUTICAL

1900 Powell St. Suite 1000 Emeryville, CA 94608 Tel|510.450.3500 Fax|510.428.0519

Exhibit 10.2 DATE: May 8, 2019 Vijay Shreedhar, PhD Dear Vijay: We are very excited to have you join Adamas Pharmaceuticals, Inc. (“the Company”). In this letter, I would like to set forth the terms and conditions of your employment relationship with the Company. Title and Responsibilities. I am pleased to offer you the full-time position of Chief Commercial Officer working at our offices in Emery

ADMS / Adamas Pharmaceuticals, Inc. / Stonepine Capital Management, LLC Passive Investment

SC 13G 1 adamas13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Adamas Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00548A106 (CUSIP Number) June 12, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropria

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2019 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36399 (Commission File Num

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2019 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36399 (Commission File Numb

Adamas Reports First Quarter 2019 Financial Results - First quarter net product sales of $11.7 million - GOCOVRI® total prescriptions grew to approximately 5,820 in Q1 2019 - Phase 3 study of ADS-5102 (GOCOVRI) in walking impairment in patients with

EX-99.1 2 adms991erq12019.htm EXHIBIT 99.1 Exhibit 99.1 Adamas Reports First Quarter 2019 Financial Results - First quarter net product sales of $11.7 million - GOCOVRI® total prescriptions grew to approximately 5,820 in Q1 2019 - Phase 3 study of ADS-5102 (GOCOVRI) in walking impairment in patients with multiple sclerosis on course to complete in Q4 2019 EMERYVILLE, Calif., May 9, 2019 - Adamas P

Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36399 ADAMAS PHARMACEUTICAL

ADMS / Adamas Pharmaceuticals, Inc. DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

Schedule 14A

DEF 14A 1 adms2019proxystatement.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the C

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2019 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction (Commission File Number) (

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2019 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction (Commission File Number) (

Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2018

EX-99.1 2 adms2018q4991.htm EXHIBIT 99.1 Exhibit 99.1 Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2018 EMERYVILLE, Calif., March 4, 2019 - Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today reported recent achievements and financial results for the fourth quarter and full-year ended December 31, 2018, along with key priorities for 2019. “We are exci

ADMS / Adamas Pharmaceuticals, Inc. S-8

As filed with the Securities and Exchange Commission on March 4, 2019 Registration No.

ADAMAS PHARMACEUTICALS, INC. 2016 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 4, 2016; AS AMENDED: MARCH 1, 2019 TERMINATION DATE: MARCH 3, 2026

Exhibit 10.7 ADAMAS PHARMACEUTICALS, INC. 2016 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 4, 2016; AS AMENDED: MARCH 1, 2019 TERMINATION DATE: MARCH 3, 2026 1. GENERAL. (a) Purpose. Awards under the Plan are intended to provide (1) an inducement material for certain individuals to enter into employment with the Company within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules

Form 10-K

10-K 1 adms1231201810k.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36399 ADAMAS PHARMACEUTICALS, INC

ADAMAS PHARMACEUTICALS, INC. SUBSIDIARIES NAME OF SUBSIDIARY JURISDICTION OF INCORPORATION Adamas Pharma, LLC Delaware, USA

Exhibit 21.1 ADAMAS PHARMACEUTICALS, INC. SUBSIDIARIES NAME OF SUBSIDIARY JURISDICTION OF INCORPORATION Adamas Pharma, LLC Delaware, USA

ADMS / Adamas Pharmaceuticals, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ADAMAS PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 00548A106 (CUSIP Number) FEBRUARY 26, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant

ADMS / Adamas Pharmaceuticals, Inc. / MACQUARIE GROUP LTD - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)* Adamas Pharmaceuticals Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 00548A106 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi

ADMS / Adamas Pharmaceuticals, Inc. / Point72 Asset Management, L.P. - SCHEDULE 13G (AMENDMENT NO. 2) Passive Investment

240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* (Name of Issuer) Adamas Pharmaceuticals, Inc. (Title of Class of Securities) Common Stock, Par Value $

ADMS / Adamas Pharmaceuticals, Inc. / Broadfin Capital, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

ADMS / Adamas Pharmaceuticals, Inc. / Went Gregory T - SC 13G/A Passive Investment

CUSIP No. 00548A 106 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Adamas Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 00548A 106 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

ADMS / Adamas Pharmaceuticals, Inc. / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Adamas Pharmaceuticals Inc (Name of Issuer) Common Stock (Title of Class of Securities) 00548A106 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

ADMS / Adamas Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Adamas Provides Preliminary Fourth Quarter and Full-Year 2018 GOCOVRI™ Sales Results and Outlines Key Priorities for 2019 -- GOCOVRI preliminary net sales of approximately $13.3 million for the fourth quarter of 2018 and approximately $34 million for

Exhibit 99.1 Adamas Provides Preliminary Fourth Quarter and Full-Year 2018 GOCOVRI™ Sales Results and Outlines Key Priorities for 2019 - GOCOVRI preliminary net sales of approximately $13.3 million for the fourth quarter of 2018 and approximately $34 million for the year - - Preliminary total prescriptions of approximately 5,700 for the fourth quarter of 2018 and approximately 15,500 for the year

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2019 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction (Commission File Number)

ADMS / Adamas Pharmaceuticals, Inc. / Brenner West Capital Advisors, LLC - SCHEDULE 13G HOLDINGS REPORT AMENDMENT Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

Adamas Reports Third Quarter 2018 Financial Results - GOCOVRI™ (amantadine) extended release capsules sales increased to $10.6 million for the third quarter, with ~4,740 fulfilled prescriptions -

Exhibit 99.1 Adamas Reports Third Quarter 2018 Financial Results - GOCOVRI™ (amantadine) extended release capsules sales increased to $10.6 million for the third quarter, with ~4,740 fulfilled prescriptions - EMERYVILLE, Calif., November 1, 2018 – Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system di

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2018 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction (Commission File Number

INSIDER TRADING, WINDOW AND PRE-CLEARANCE POLICY

Exhibit 10.2 September 13, 2018 Via Hand Delivery Richard A. King c/o Adamas Pharmaceuticals, Inc. Re: Separation and Consulting Agreement Dear Richard: This letter sets forth the substance of the separation agreement (the “Agreement”) that Adamas Pharmaceuticals, Inc. (the “Company”) is offering to you to aid in your employment transition. 1.SEPARATION DATE. Your employment with the Company will

ADMS / Adamas Pharmaceuticals, Inc. 10-Q (Quarterly Report)

10-Q 1 adms10q09302018.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Nu

EIGHTH AMENDMENT TO OFFICE LEASE AGREEMENT

Exhibit 10.1 EIGHTH AMENDMENT TO OFFICE LEASE AGREEMENT This EIGHTH AMENDMENT TO LEASE (“Amendment”), dated for reference purposes only as of the 2 day of August, 2018, is entered into by and between KBSIII Towers at Emeryville, LLC, a Delaware limited liability company (“Landlord”), and ADAMAS PHARMACEUTICALS, INC., a Delaware corporation (formerly known as Neuromolecular Pharmaceuticals, Inc.) (

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2018 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction (Commission File Number)

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2018 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction (Commission File Numb

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2018 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction (Commission File Numb

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 adms8-kq22018.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2018 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdicti

Adamas Reports Second Quarter 2018 Financial Results - GOCOVRI™ (amantadine) extended release capsules product sales reached $7.6 million for the second quarter -

Exhibit 99.1 Adamas Reports Second Quarter 2018 Financial Results - GOCOVRI™ (amantadine) extended release capsules product sales reached $7.6 million for the second quarter - EMERYVILLE, Calif., August 2, 2018 – Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today reported financial results and pipeline updates for the second quarter ended June 30, 2018. “We continue to be pleased with the progress

ADMS / Adamas Pharmaceuticals, Inc. 10-Q (Quarterly Report)

10-Q 1 adms10q06302018.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001

NON-EMPLOYEE DIRECTOR COMPENSATION

Exhibit 10.1 NON-EMPLOYEE DIRECTOR COMPENSATION Cash Compensation The annual cash compensation payable to non-employee directors of Adamas Pharmaceuticals, Inc. is as follows, payable quarterly in arrears: Retainer Amount Board Member Compensation Annual Board Member $40,000 Additional Lead Independent Director $22,500 Additional Committee Chair Compensation Audit Committee $20,000 Compensation Co

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2018 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction (Commission File Number) (I

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2018 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction (Commission File Number) (IR

Adamas Reports First Quarter 2018 Financial Results GOCOVRI™ (amantadine) extended release capsules product sales hit $2.6 million for the first quarter of commercialization, with 1,608 fulfilled prescriptions Received positive feedback from the U.S.

EX-99.1 2 adms991erq12018.htm EXHIBIT 99.1 Exhibit 99.1 Adamas Reports First Quarter 2018 Financial Results GOCOVRI™ (amantadine) extended release capsules product sales hit $2.6 million for the first quarter of commercialization, with 1,608 fulfilled prescriptions Received positive feedback from the U.S. Food and Drug Administration (FDA) on the clinical development program for ADS-4101 in patien

ADMS / Adamas Pharmaceuticals, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36399 ADAMAS PHARMACEUTICALS,

ADMS / Adamas Pharmaceuticals, Inc. DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

ADMS / Adamas Pharmaceuticals, Inc. DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

ADMS / Adamas Pharmaceuticals, Inc. / Broadfin Capital, LLC Passive Investment

SC 13G 1 d787516713-g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Adamas Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00548A106 (CUSIP Number) April 19, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropri

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2018 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction (Commission File Number)

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2018 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction (Commission File Number)

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2018 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction (Commission File Number) (

Regulation FD Disclosure

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2018 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction (Commission F

ADMS / Adamas Pharmaceuticals, Inc. S-8

Document As filed with the Securities and Exchange Commission on February 22, 2018 Registration No.

ADAMAS PHARMACEUTICALS, INC. 2016 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 4, 2016; AS AMENDED: NOVEMBER 28, 2017 TERMINATION DATE: MARCH 3, 2026

Exhibit Exhibit 99.5 ADAMAS PHARMACEUTICALS, INC. 2016 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 4, 2016; AS AMENDED: NOVEMBER 28, 2017 TERMINATION DATE: MARCH 3, 2026 1. GENERAL. (a) Purpose. Awards under the Plan are intended to provide (1) an inducement material for certain individuals to enter into employment with the Company within the meaning of Rule 5635(c)(4) of the NASDAQ L

Financial Statements and Exhibits, Results of Operations and Financial Condition

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2018 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction (Commission F

Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2017

Exhibit Exhibit 99.1 Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2017 EMERYVILLE, Calif., February 22, 2018 - Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today reported recent achievements and financial results for the fourth quarter and full-year ended December 31, 2017 . ?I?m very proud of the accomplishments made by the Adamas team in 2017, espe

ADMS / Adamas Pharmaceuticals, Inc. 10-K (Annual Report)

10-K 1 adms1231201710k.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36399 ADAMAS PHARMACEUTICALS, INC

SEVENTH AMENDMENT TO LEASE

Exhibit 10.38 SEVENTH AMENDMENT TO LEASE THIS SEVENTH AMENDMENT TO LEASE (“Amendment”), dated for reference purposes only as of the 16th day of January, 2018 is entered into by and between KBSIII Towers at Emeryville, LLC, a Delaware limited liability company (“Landlord”), and ADAMAS PHARMACEUTICALS, INC., a Delaware corporation (formerly known as Neuromolecular Pharmaceuticals, Inc.) (“Tenant”).

SECURED PROMISSORY NOTE (Subsequent Tranche Loan)

Exhibit 10.37 SECURED PROMISSORY NOTE (Subsequent Tranche Loan) THIS NOTE AND THE OBLIGATIONS REPRESENTED HEREBY MAY NOT BE TRANSFERRED EXCEPT IN COMPLIANCE WITH THE TERMS AND PROVISIONS OF THE LOAN AGREEMENT REFERRED TO BELOW. TRANSFERS OF THIS NOTE AND THE OBLIGATIONS REPRESENTED HEREBY MUST BE RECORDED IN THE REGISTER MAINTAINED BY THE BORROWER PURSUANT TO THE TERMS OF THE LOAN AGREEMENT. IN AD

ADMS / Adamas Pharmaceuticals, Inc. / BOW STREET, LLC - ADAMAS PHARMACEUTICALS, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Adamas Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00548A106 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p

ADMS / Adamas Pharmaceuticals, Inc. / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Adamas Pharmaceuticals Inc (Name of Issuer) Common Stock (Title of Class of Securities) 00548A106 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi

JOINT FILING AGREEMENT

Invesco Joint Filing Agreement JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) (l) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing of the attached Schedule 13G, and any and all amendments thereto, and expressly authorize Invesco Ltd.

ADMS / Adamas Pharmaceuticals, Inc. / Brenner West Capital Advisors, LLC - 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

ADMS / Adamas Pharmaceuticals, Inc. / Point72 Asset Management, L.P. - SCHEDULE 13G/A, AMENDMENT #1 Passive Investment

SC 13G/A 1 p23743055a.htm SCHEDULE 13G/A, AMENDMENT #1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ADAMAS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 00548A106 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing o

ADMS / Adamas Pharmaceuticals, Inc. / MDV VII LP - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* ADAMAS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00548A106 (CUSIP Number) Mohr Davidow Ventures 777 Mariners Island Blvd, Suite 550 San Mateo, California 94404 (Name, Address and Teleph

ADMS / Adamas Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

ADMS / Adamas Pharmaceuticals, Inc. / Kerrisdale Advisers, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

ADMS / Adamas Pharmaceuticals, Inc. / Went Gregory T - SC 13G/A Passive Investment

CUSIP No. 00548A 106 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Adamas Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 00548A 106 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

Underwriting Agreement, dated January 23, 2018, by and among the Company and Merrill Lynch, Pierce, Fenner & Smith Incorporated, Leerink Partners LLC, and Evercore Group L.L.C., as representatives of the Underwriters named therein

Exhibit 1.1 EXECUTION ADAMAS PHARMACEUTICALS, INC. (a Delaware corporation) 3,000,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: January 23, 2018 ADAMAS PHARMACEUTICALS, INC. (a Delaware corporation) 3,000,000 Shares of Common Stock UNDERWRITING AGREEMENT January 23, 2018 Merrill Lynch, Pierce, Fenner & Smith Incorporated Leerink Partners LLC Evercore Group L.L.C. as Representative(s) of

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2018 Adamas Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction (Commission File Number

3,000,000 Shares Common Stock

Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.

Subject to Completion Preliminary Prospectus Supplement dated January 22, 2018

Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.

Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2018 Adamas Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction (Commission File Number

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2018 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction (Commission Fi

ADMS / Adamas Pharmaceuticals, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment

SC 13G/A 1 ADMSSC13GA1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ADAMAS PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 00548A106 (CUSIP Number) DECEMBER 31, 2017 (Date of event which requires filing of this statement) Check the a

Adamas Pharmaceuticals 8-K (Current Report/Significant Event)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2017 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction (Commission Fi

Adamas Reports Recent Achievements and Third Quarter 2017 Financial Results

EX-99.1 2 adms991erq32017.htm EXHIBIT 99.1 Exhibit 99.1 Adamas Reports Recent Achievements and Third Quarter 2017 Financial Results EMERYVILLE, Calif., November 2, 2017 – Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today reported recent achievements and financial results for the third quarter ended September 30, 2017. “We are thrilled that GOCOVRI (amantadine) extended release capsules is approved

AMENDED AND RESTATED COMMERCIAL SUPPLY AGREEMENT (Amantadine HCl extended release capsules)

Exhibit 10.1 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. EXECUTION COPY AMENDED AND RESTATED COMMERCIAL SUPPLY AGREEMENT (Amantadine HCl extended release capsules) This Amended and Restated Commercial

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36399 ADAMAS PHARMACEUTICA

Amended and Restated API Supply Agreement by and between Adamas Pharma, LLC and Moehs Ibérica, S.L. (incorporated by reference to Exhibit 10.2 to the Form 10-Q filed by Adamas Pharmaceuticals, Inc. on November 2, 2017, File No. 001-36399)

Exhibit 10.2 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. CONFIDENTIAL AMENDED AND RESTATED API SUPPLY AGREEMENT This Amended and Restated API Supply Agreement (this “Agreement”) is effective as of Jul

JOINT FILING AGREEMENT

EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of this Schedule 13G (including additional amendments thereto) with respect to the shares of Common Stock, par value $0.001 per share, of Adamas Pharmaceuticals, Inc. This Joint Filing Agre

ADMS / Adamas Pharmaceuticals, Inc. / Kerrisdale Advisers, LLC - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

ADMS / Adamas Pharmaceuticals, Inc. / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ADAMAS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 00548A106 (CUSIP Number) October 26, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2017 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction (Commission File Number

ADMS / Adamas Pharmaceuticals, Inc. / GREAT POINT PARTNERS LLC Passive Investment

SC 13G/A 1 c89500sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Adamas Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00548A106 (CUSIP Number) September 30, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design

Adamas Pharmaceuticals 8-K (Current Report/Significant Event)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2017 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction (Commission Fil

Adamas Pharmaceuticals 8-K (Current Report/Significant Event)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2017 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction (Commission

Adamas Pharmaceuticals 8-K (Current Report/Significant Event)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2017 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction (Commission

ADMS / Adamas Pharmaceuticals, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment

SC 13G 1 ADMSSC13G.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ADAMAS PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 00548A106 (CUSIP Number) AUGUST 29, 2017 (Date of event which requires filing of this statement) Check the appropriate box to design

Adamas Reports Recent Achievements and Second Quarter 2017 Financial Results

Exhibit Exhibit 99.1 Adamas Reports Recent Achievements and Second Quarter 2017 Financial Results EMERYVILLE, Calif., August 8, 2017 ? Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today reported recent achievements and financial results for the second quarter ended June 30, 2017 . ?This is a very exciting time for Adamas, as we are potentially at the cusp of transitioning from a company focused on

Adamas Pharmaceuticals 8-K (Current Report/Significant Event)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2017 ADAMAS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36399 42-1560076 (State or other jurisdiction (Commission File

1900 Powell St. Suite 750 Emeryville, CA 94608 Tel|510.450.3500 Fax|510.428.0519

Exhibit 10.1 April 14, 2017 Richard King Dear Richard: We are very excited to have you join Adamas Pharmaceuticals, Inc. (“the Company”). In this letter, I would like to set forth the terms and conditions of your employment relationship with the Company. Title and Responsibilities. I am pleased to offer you the full-time position of Chief Operating Officer working at our offices in Emeryville, CA.

1900 Powell St. Suite 750 Emeryville, CA 94608 Tel|510.450.3500 Fax|510.428.0519

Exhibit 10.2 June 26, 2017 Alfred Merriweather Dear Alf: We are very excited to have you join Adamas Pharmaceuticals, Inc. (“the Company”). In this letter, I would like to set forth the terms and conditions of your employment relationship with the Company. Title and Responsibilities. I am pleased to offer you the full-time position of Chief Financial Officer working at our offices in Emeryville, C